patient stratification

AltraBio is a contract research company specializing in advanced biological data analysis and bioinformatics services, helping biopharma, cosmetic, and clinical R&D organizations extract insights from cytometry, omics, and medical data using AI, machine learning, and biostatistics. It serves pharmaceutical companies, biotech startups, dermo-cosmetic leaders, and university hospitals worldwide.

automated gatingbioinformatics pipeline developmentbiomarker discoverybiostatisticsbulk transcriptomicscytometry data analysishigh-dimensional panel analysismachine learningproteomicsreal-world data miningsingle-cell RNA-seq analysisstatistical modelingtarget identification

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) uses explainable AI and machine learning to accelerate drug discovery and development for biopharma teams. Its platform combines biology-aware data harmonization, Causal AI analytics, and structured, auditable decision support to turn multi-omic and clinical data into patient subgroups, translational signals, and candidate rankings. bfLEAP® was developed in partnership with Johns Hopkins University Applied Physics Laboratory, and its neuroscience data infrastructure is built with the Lieber Institute for Brain De

Causal AI analyticsdata harmonizationdecision supportdrug target discoveryexplainable AImachine learningpatient subgroup discovery

Foli Bio is building a molecular data layer for gut biology through stool-derived host RNA. Its Foli-seq™ platform profiles host RNA from naturally shed gut epithelial and immune cells to reveal mucosal inflammation, barrier function, disease biology, and therapeutic response, enabling non-invasive longitudinal transcriptomic readouts for translational studies, biomarker discovery, clinical diagnostics, and precision medicine.

assay developmentbiomarker discoveryhost gut transcriptomicsNGS bioinformaticspharmacodynamic monitoringstool-derived host RNA profiling